Y Richard Wang

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi request reprint Prescription drug formulary design, preferred-product marketshare, and formulary noncompliance: a study of proton-pump inhibitors
    Y Richard Wang
    Health Services Research and Policy Analysis, Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850 5437, USA
    Manag Care Interface 18:39-45. 2005
  2. ncbi request reprint The Chinese pharmaceutical market at the crossroads: pro-competition solutions to improve access, quality and affordability
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850 5437, USA
    Appl Health Econ Health Policy 4:147-51. 2005
  3. ncbi request reprint Difference in the use of preventive services between fee-for-service plans and HMOs: is more better?
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Del 19850 5437, USA
    Am J Manag Care 9:293-301. 2003
  4. ncbi request reprint Price competition in the Chinese pharmaceutical market
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals 1800 Concord Pike, Wilmington, DE, 19850 5437, USA
    Int J Health Care Finance Econ 6:119-29. 2006
  5. ncbi request reprint Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary
    Y Richard Wang
    Public Policy Department AstraZeneca Pharmaceuticals, FOC 3 CE 317, 1800 Concord Pike, Wilmington, DE 19850 5437, USA
    Am J Manag Care 9:686-96. 2003
  6. ncbi request reprint The prevalence of diagnosed cutaneous manifestations during ambulatory diabetes visits in the United States, 1998-2002
    Y Richard Wang
    Public Policy Department, Astra Zeneca Pharmaceuticals, Wilmington, Del 19850 5437, USA
    Dermatology 212:229-34. 2006
  7. ncbi request reprint Spillover effects of restrictive drug formularies: a case study of PacifiCare in California
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Del 19850 5437, USA
    Am J Manag Care 11:24-6. 2005
  8. ncbi request reprint Lack of effect of guideline changes on LDL cholesterol reporting and control for diabetes visits in the U.S., 1995-2004
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, FOC 3 CE 417, 1800 Concord Pike, Wilmington, DE 19850 5437, USA
    Diabetes Care 28:2942-4. 2005
  9. ncbi request reprint Screening and treatment of hypercholesterolemia for prevention of coronary heart disease
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850, USA
    Manag Care Interface 19:25-9. 2006
  10. ncbi request reprint Preventive care in managed care and fee-for-service plans: is it cost effective?
    Y Richard Wang
    Health Services Research and Policy Analysis, Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Manag Care Interface 16:47-50. 2003

Detail Information

Publications16

  1. ncbi request reprint Prescription drug formulary design, preferred-product marketshare, and formulary noncompliance: a study of proton-pump inhibitors
    Y Richard Wang
    Health Services Research and Policy Analysis, Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850 5437, USA
    Manag Care Interface 18:39-45. 2005
    ..They found that although drug formulary restrictiveness increases the use of preferred products, it also leads to a high level of formulary noncompliance. The net financial effect on drug spending is ambiguous...
  2. ncbi request reprint The Chinese pharmaceutical market at the crossroads: pro-competition solutions to improve access, quality and affordability
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850 5437, USA
    Appl Health Econ Health Policy 4:147-51. 2005
    ..Working together, these two proposals would improve access to and the quality and affordability of pharmaceuticals in China...
  3. ncbi request reprint Difference in the use of preventive services between fee-for-service plans and HMOs: is more better?
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Del 19850 5437, USA
    Am J Manag Care 9:293-301. 2003
    ....
  4. ncbi request reprint Price competition in the Chinese pharmaceutical market
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals 1800 Concord Pike, Wilmington, DE, 19850 5437, USA
    Int J Health Care Finance Econ 6:119-29. 2006
    ..Policy changes that encourage bioequivalent local products and accelerate global product approvals will enhance price competition in China...
  5. ncbi request reprint Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary
    Y Richard Wang
    Public Policy Department AstraZeneca Pharmaceuticals, FOC 3 CE 317, 1800 Concord Pike, Wilmington, DE 19850 5437, USA
    Am J Manag Care 9:686-96. 2003
    ..Market penetration of HMOs affect physician practice styles for non-HMO patients...
  6. ncbi request reprint The prevalence of diagnosed cutaneous manifestations during ambulatory diabetes visits in the United States, 1998-2002
    Y Richard Wang
    Public Policy Department, Astra Zeneca Pharmaceuticals, Wilmington, Del 19850 5437, USA
    Dermatology 212:229-34. 2006
    ..The prevalence of diabetes has been rapidly increasing. Previous reports indicated that diabetics are prone to certain cutaneous diseases...
  7. ncbi request reprint Spillover effects of restrictive drug formularies: a case study of PacifiCare in California
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Del 19850 5437, USA
    Am J Manag Care 11:24-6. 2005
    ..A restrictive drug formulary may influence how physicians treat other, unaffiliated patients, a phenomenon known as the "spillover effect." In a previous study we found significant spillover effects from Maine's Medicaid formulary...
  8. ncbi request reprint Lack of effect of guideline changes on LDL cholesterol reporting and control for diabetes visits in the U.S., 1995-2004
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, FOC 3 CE 417, 1800 Concord Pike, Wilmington, DE 19850 5437, USA
    Diabetes Care 28:2942-4. 2005
  9. ncbi request reprint Screening and treatment of hypercholesterolemia for prevention of coronary heart disease
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850, USA
    Manag Care Interface 19:25-9. 2006
    ..Drug therapy recommendation also decreasedwith greater NCEP risk. Despite improvements, underscreening and undertreatment of hypercholesterolemia persists in outpatient visits...
  10. ncbi request reprint Preventive care in managed care and fee-for-service plans: is it cost effective?
    Y Richard Wang
    Health Services Research and Policy Analysis, Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Manag Care Interface 16:47-50. 2003
    ..Effective screening strategies must be identified, especially for the underserved, low-income population...
  11. ncbi request reprint Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States
    Y Richard Wang
    Department of Medicine, Temple University Hospital, Philadelpia, PA 19140, USA
    Arch Intern Med 167:141-7. 2007
    ..Hypertension guidelines in the United States tend to have more aggressive treatment recommendations than those in European countries...
  12. ncbi request reprint The quantity and quality of worldwide new drug introductions, 1982-2003
    Henry G Grabowski
    Department of Economics, Duke University, Durham, North Carolina, USA
    Health Aff (Millwood) 25:452-60. 2006
    ..S. firms overtook their European counterparts in innovative performance or the introduction of first-in-class, biotech, and orphan products. The United States also became the leading market for first launch...
  13. ncbi request reprint The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s
    Patricia M Danzon
    Health Care Systems Department, The Wharton School, University of Pennsylvania, Philadelphia, 19104 6218, USA
    Health Econ 14:269-92. 2005
    ..Controlling for expected price and volume, country effects for the likely parallel export countries are significantly negative...
  14. ncbi request reprint High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial
    J Sanford Schwartz
    Department of Medicine, Leonard Davis Institute of Health Economics, Wharton School, Center for Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA
    Am J Manag Care 9:417-24. 2003
    ..Angiotensin-converting enzyme (ACE) inhibitors reduce heart failure death and hospitalization. Prescribed doses often are lower than randomized clinical trial (RCT) targets and practice guideline recommendations...
  15. ncbi request reprint Spillover effects of restrictive drug formularies in the statin class: a descriptive study of the Medicaid preferred drug list in Texas
    Y Richard Wang
    Department of Medicine, Temple University Hospital, Philadelphia, Pennsylvania 19140, USA
    Manag Care Interface 19:32-4. 2006
    ..Therefore, the restrictive Medicaid PDL in Texas spilled over to non-Medicaid patients...
  16. ncbi request reprint Lack of effect of guideline changes on hypertension control for patients with diabetes in the U.S., 1995-2005
    Y Richard Wang
    Department of Medicine, Temple University Hospital, Philadelphia, PA 19140, USA
    Diabetes Care 30:49-52. 2007
    ..S. using patients without diabetes as the control group for the time trend...